Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas

NCT ID: NCT06842303

Last Updated: 2025-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-06

Study Completion Date

2027-06-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic resonance imaging sequences, such as high resolution applied to diffusion sequences (Harder et al., 2022) or magnetic resonance elastography (MRE) (Steinkohl et al., 2021), could help address this issue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreas Adenocarcinomas

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with a resectable pancreatic lesion

Pancreatic resection surgery

Group Type EXPERIMENTAL

Magnetic resonance elastography (MRE).

Intervention Type DEVICE

Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure

High-resolution diffusion sequence in MRI

Intervention Type DEVICE

High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.

Patient with a borderline pancreatic lesion

Potential pancreatic resection surgery after chemotherapy.

Group Type EXPERIMENTAL

Magnetic resonance elastography (MRE).

Intervention Type DEVICE

Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure

High-resolution diffusion sequence in MRI

Intervention Type DEVICE

High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.

Patient with locally advanced pancreatic lesion.

Chemotherapy treatment.

Group Type EXPERIMENTAL

Magnetic resonance elastography (MRE).

Intervention Type DEVICE

Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure

High-resolution diffusion sequence in MRI

Intervention Type DEVICE

High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic resonance elastography (MRE).

Magnetic resonance elastography (MRE) is an imaging technique that measures tissue stiffness by assessing the deformation waves produced under external pressure

Intervention Type DEVICE

High-resolution diffusion sequence in MRI

High-resolution diffusion sequence in MRI is an imaging technique that uses the movement of water molecules within tissues to generate detailed images.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT;
* Adult patient: age ≥ 18 years;
* Patient affiliated with a social security system or beneficiary of such a system;
* Patient who has received complete information about the research organization and has signed an informed consent form.

Exclusion Criteria

* Patient with a contraindication to MRI.
* Person referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code.

* Pregnant woman, parturient, or breastfeeding mother;
* Minor (non-emancipated) individual;
* Adult individual under legal protection (guardianship, curatorship, or judicial safeguard);
* Adult individual unable to express consent.
* Person deprived of liberty by a judicial or administrative decision, or person undergoing psychiatric care pursuant to Articles L. 32-12-1 and L. 3213-1 of the French Public Health Code.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Hospital, Nancy, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

LECLERC Julie

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU Nancy

Vandœuvre-lès-Nancy, France, France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Guillaume DROUOT, PhD

Role: CONTACT

0385157666 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

DROUOT Guillaume

Role: primary

0383157666

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A01375-42

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.